BridgeBio Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2830 bridgebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma, Inc.

Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up - Mar 10th, 2026 2:16 pm
Qualcomm downgraded, Rivian upgraded: Wall Street's top analyst calls - Mar 10th, 2026 7:34 am
Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)? - Mar 7th, 2026 2:10 pm
How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline - Mar 7th, 2026 12:07 am
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating - Mar 6th, 2026 8:20 am
BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms - Mar 6th, 2026 1:53 am
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - Mar 4th, 2026 5:30 am
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success - Mar 3rd, 2026 12:21 am
Is BridgeBio Pharma (BBIO) Attractive After Recent Pullback And Late Stage Pipeline Progress? - Mar 2nd, 2026 2:12 am
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Feb 24th, 2026 10:03 pm
BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary - Feb 24th, 2026 6:03 pm
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates - Feb 24th, 2026 5:30 pm
BridgeBio Pharma Q4 Earnings Call Highlights - Feb 24th, 2026 4:26 pm
BridgeBio Pharma: Q4 Earnings Snapshot - Feb 24th, 2026 2:24 pm
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates - Feb 24th, 2026 2:01 pm
BridgeBio to Participate in March Investor Conferences - Feb 23rd, 2026 5:30 am
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Feb 18th, 2026 3:14 pm
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact - Feb 17th, 2026 10:45 pm
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Feb 17th, 2026 4:22 pm
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition - Feb 17th, 2026 11:07 am